July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Small PEDF-derived peptides mitigate choroidal neovascularization
Author Affiliations & Notes
  • Jack Henkin
    Chemistry, Northwestern University, Evanston, Illinois, United States
  • Ignacio Melgar-Asensio
    Chemistry, Northwestern University, Evanston, Illinois, United States
  • Soesiawati R. Darjatmoko
    Ophthalmology & Visual Sciences, University of Wisconsin School of Medicine, Wisconsin, United States
  • Shoujian Wang
    Ophthalmology & Visual Sciences, University of Wisconsin School of Medicine, Wisconsin, United States
  • Christine M. Sorenson
    Pediatrics, University of Wisconsin School of Medicine, Madison, Wisconsin, United States
  • Daniel M Albert
    Casey Eye Institute, Oregon Health Sciences University, Portland, Oregon, United States
  • Reshma Bhowmick
    Thoracic & Cardiovascular Surgery, MD Anderson Cancer Center, Houston, Texas, United States
  • Olga Volpert
    Cancer Biology, MD Anderson Cancer Center, Houston, Texas, United States
  • Nader Sheibani
    Ophthalmology & Visual Sciences, University of Wisconsin School of Medicine, Wisconsin, United States
  • Footnotes
    Commercial Relationships   Jack Henkin, Northwestern University (P); Ignacio Melgar-Asensio, Northwestern University (P); Soesiawati Darjatmoko, None; Shoujian Wang, None; Christine Sorenson, None; Daniel Albert, None; Reshma Bhowmick, None; Olga Volpert, Northwestern University (P); Nader Sheibani, None
  • Footnotes
    Support  EY022883
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 355. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jack Henkin, Ignacio Melgar-Asensio, Soesiawati R. Darjatmoko, Shoujian Wang, Christine M. Sorenson, Daniel M Albert, Reshma Bhowmick, Olga Volpert, Nader Sheibani; Small PEDF-derived peptides mitigate choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 2019;60(9):355.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Abnormal migration and proliferation of endothelial cells (EC) drive exudative AMD, diabetic retinopathy and retinopathy of prematurity with adverse effects on vision. Decreased levels of endogenous inhibitors of angiogenesis, including pigment epithelium derived factor (PEDF), make a significant contribution to these pathologies. A PEDF surface helical 34-mer peptide carries its antiangiogenic activity. PEDF peptides of 18-34 amino acids show this activity but are too large for therapeutic use. Here we sought smaller peptides derived from the 34-mer, having potent anti-angiogenic activity, to mitigate choroidal neovascularization (CNV).

Methods : Truncation of the PEDF 34-mer led to identification of anti-angiogenic smaller peptides. In addition, further changes identified the N-terminal dicarboxylic acid (DCA) modified octa- and nonapeptides, where DCA charge compensation by substitution of Asn for an Asp residue, optimized apoptotic response in activated EC. Two potent small peptides (8-mer, 9-mer) were delivered by intravitreal (IVT) injection of mice subjected to laser-induced CNV. The degrees of neovascularization was assessed by immunostaining of flatmounts with ICAM-2 antibody and measurements of area of neovascularization. The ocular safety was also assessed by electroretinography (ERG) and histological evaluation in mice and rabbits.

Results : A single IVT injection of 2-4 nmoles of either peptide, 2-5 days prior to laser treatment, resulted in a significant decrease in CNV at day 14. The smaller peptide (zero net-charge) was also active when administered as bid eye drops. No inflammation or ERG effects were observed. In addition, the peptides at 100 µM, were not cytotoxic to various retinal cell lines. Histopathology was negative in rabbit eyes injected with 300 µg of either peptide.

Conclusions : A small anti-angiogenic pharmacophore was defined within the PEDF sequence (Y-D-L-Y-R-V). New modifications (adipic-X-Y-N-L-Y-R-V…) yielded practical, CNV-mitigating peptides that are potently anti-angiogenic, without direct neutralization of vascular endothelial growth factor.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×